CoChat
Sign Up
Cited by 87Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Innate immune system and inflammation in Alzheimer’s disease: From pathogenesis to treatment

Serpente, Maria, Bonsi, Rossana, Scarpini, Elio, Galimberti, Daniela·2014·Neuroimmunomodulation
DOI 10.1159/000356529
Open this paper in CoChat — free account

Abstract

Immune activation and inflammation, likely triggered by amyloid-beta (Aβ) deposition, play a remarkable role in the pathogenesis of Alzheimer's disease (AD), which is the most frequent cause of dementia in the elderly. The principal cellular elements of the brain innate immune system likely to be involved in such processes are microglia. In an attempt to search for new disease-modifying drugs, the immune system has been addressed, with the aim of removing deposition of Aβ or tau by developing vaccines and humanized monoclonal antibodies. The aim of this review is to summarize the current evidence regarding the role played by microglia and inflammatory molecules in the pathogenesis of AD. In addition, we will discuss the main active and passive immunotherapeutic approaches.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000356529

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 63

  1. 1 Selkoe DJ: Translating cell biology into thera- peutic advances in Alzheimer's disease. Na- ture 1999; 399:A23-A31.
  2. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Müller-Hill B: The precursor of Alzheimer's disease amyloid A4 protein re- sembles a cell-surface receptor. Nature 1987; 325: 733-736
  3. Finch CE, Morgan TE: Systemic inflamma- tion, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr Alzheimer Res 2007; 4: 185-189.
  4. Tuppo EE, Arias HR: The role of inflamma- tion in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37: 289-305.
  5. Akiyama H, Barger S, Barnum S, et al: Inflam- mation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
  6. Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, Martins RN: Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res Rev 2003; 43: 1-16.
  7. Bessis A, Bechade C, Bernard D, Roumier A: Microglial control of neuronal death and syn- aptic properties. Glia 2007; 55: 233-238.
  8. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A: Physiology of microglia. Physiol Rev 2011; 91: 461-553.
  9. Dheen ST, Kaur C, Ling EA: Microglial acti- vation and its implications in the brain dis- eases. Curr Med Chem 2007; 14: 1189-1197.
  10. Czeh M, Gressens P, Kaindl AM: The yin and yang of microglia. Dev Neurosci 2011; 33: 199-209.
  11. Combs CK, Karlo JC, Kao SC, Landreth GE: β-Amyloid stimulation of microglia anti monocytes results in TNFα-dependent ex- pression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 2001; 21: 1179-1188.
  12. Ho GJ, Drego R, Hakimian E, Masliah E: Mechanisms of cell signaling and inflamma- tion in Alzheimer's disease. Curr Drug Tar- gets Inflamm Allergy 2005; 4: 247-256.
  13. Verri M, Pastoris O, Dossena M, Aquilani R, Guerriero F, Cuzzoni G, Venturini L, Ricevu- ti G, Bongiorno AI: Mitochondrial altera- tions, oxidative stress and neuroinflamma- tion in Alzheimer's disease. Int J Immuno- pathol Pharmacol 2012; 25: 345-353.
  14. Li C, Zhao R, Gao K, Wei Z, Yin MY, Lau LT, Chui D, Hoi Yu AC: Astrocytes: implications for neuroinflammatory pathogenesis of Alz- heimer's disease. Curr Alzheimer Res 2011; 8: 67-80.
  15. Schousboe A, Westergaard N, Sonnerwald U, Petersen SB, Yu AC, L: Hertz: Regulatory role of astrocytes for neuronal biosynthesis and homeostasis of glutamate and GABA. Prog Brain Res 1992; 94: 199-211.
  16. Aloisi F: Cytokine production; in Kettnman H, Ransom B (eds): Neuroglia. Oxford, Ox- ford University, 2005, pp 285-301.
  17. Strack A, Asensio VC, Campbell IL, Schluter D, Deckert M: Chemokines are differentially expressed by astrocytes, microglia and in- flammatory leukocytes in Toxoplasma en- cephalitis and critically regulated by interferon-γ. Acta Neuropathol 2002; 103: 458-468.
  18. Serpente/Bonsi/Scarpini/Galimberti Neuroimmunomodulation 2014;21:79-87 DOI: 10.1159/000356529 86 · DOI
  19. Maccioni RB, Rojo LE, Fernandez JA, Kuljis RO: The role of neuroimmunomodulation in Alzheimer's disease. Ann N Y Acad Sci 2009; 1153: 240-246.
  20. Blasko I, Veerhuis R, Stampfer-Kountchev M, Saurwein-Teissl M, Eikelenboom P, Grub- eck-Loebenstein B: Costimulatory effects of interferon-γ and interleukin-1β or tumor ne- crosis factor-α on the synthesis of Aβ1-40 and Aβ1-42 by human astrocytes. Neurobiol Dis 2000; 7: 682-689.
  21. White JA, Manelli AM, Holmberg KH, Van Eldik LJ, Ladu MJ: Differential effects of oligomeric and fibrillar amyloid-β1-42 on as- trocyte-mediated inflammation. Neurobiol Dis 2005; 18: 459-465.
  22. Friedman WJ: Cytokines regulate expression of the type 1 interleuken-1 receptor in rat hip- pocampal neurons and glia. Exp Neurol 2001; 168: 23-31.
  23. Li Y, Barger SW, Liu L, Mrak RE, Griffin WST: S100-β induction of the pro-inflamma- tory cytokine interleukin-6 in neurons: impli- cations for Alzheimer pathogenesis. J Neuro- chem 2000; 74: 143-150.
  24. Renauld AE, Spengler RN: Tumor necrosis factor expressed by primary hippocampal neurons SH-SY5Y cells is regulated by α 2 - adrenergic receptor activation. J Neurosci Res 2002; 67: 264-274.
  25. Walker D, McGeer E, McGeer P: Involvement of inflammation and complement in Alz- heimer's disease: Clinical Neuroimmunology. Oxford, Blackwell Scientific, 1997, pp 172- 188.
  26. McGeer E, McGeer P: Inflammatory cyto- kines in the CNS. CNS Drugs 1997; 7: 214- 287.
  27. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B: TNFα plus IFNγ in- duce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. FASEB J 1999; 13: 63-68.
  28. Eikelenboom P, Van Gool WA: Neuroinflam- matory perspectives on the two faces of Alz- heimer's disease. J Neural Transm 2004; 111: 281-294.
  29. Mrak RE, Griffin WST: Interleukin-1, neuro- inflammation, and Alzheimer's disease. Neu- robiol Aging 2001; 22: 903-908. 31 Mackenzie IR: Anti-inflammatory drugs and Alzheimer type pathologyin aging. Neurology 2000; 54: 732-734.
  30. Benveniste EN: Cytokine actions in the cen- tral nervous system. Cytokine Growth Factor Rev 1998; 9: 259-275.
  31. Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF: Proliferation of astrocytes in vi- tro in response to cytokines: a primary role for tumor necrosis factor. J Immunol 1990; 144: 129-135.
  32. Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH: Progressive decline in avoidance learning paralleled by inflammatory neurode- generation in transgenic mice expressing in- terleukin 6 in the brain. Proc Natl Acad Sci USA 1997; 94: 1500-1505.
  33. Van Wagoner NJ, Oh JW, Repovic P, Ben- veniste EN: IL-6 (IL-6) production by astro- cytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J Neurosci 1999; 19: 5236-5244.
  34. Smith JA, Das A, Ray SK, Banik NL: Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 2012; 87: 10-20.
  35. Galimberti D, Venturelli E, Fenoglio C, Guidi I, Villa C, Bergamaschini L, Cortini F, Sca- labrini D, Baron P, Vergani C, Bresolin N, Scarpini E: Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and fronto- temporal lobar degeneration. J Neurol 2008; 255: 539-544.
  36. Owens T, Babcock AA, Millward JM, Toft- Hansen H: Cytokine and chemokine inter- regulation in the inflamed or injured CNS. Brain Res Rev 2005; 48: 178-184.
  37. Xia M, Hyman BT: Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol 1999; 5: 32- 41.
  38. Lue LF, Rydel RE, Brigham EF, Yang LB, Hampel H, Murphy GM, Brachova L, Yan SD, Walker DG, Shen Y, Rogers J: Inflammatory repertoire of Alzheimer's disease and nonde- mented elderly microglia in vitro. Glia 2001; 35: 72-79.
  39. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT: Immunohistochemical study of the β-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's dis- ease brains. Am J Pathol 1998; 153: 31-37.
  40. Delrieu J, Piau A, Caillaud C, Voisin T, Vellas B: Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy. CNS Drugs 2011; 25: 213- 226.
  41. McGeer PL, Schulzer M, McGeer EG: Arthri- tis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurolo- gy 1996; 47: 425-432.
  42. Galimberti D, Scarpini E: Progress in Alz- heimer's disease. J Neurol 2012; 259: 201-211.
  43. Fu HJ, Liu B, Frost JL, Lemere CA: Amyloid-β immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets 2010; 9: 197-206.
  44. Morgan D: Immunotherapy for Alzheimer's disease. J Alzheimer Dis 2006; 9: 425-432.
  45. Solomon B, Koppel R, Hanan E, Katzav T: Monoclonal antibodies inhibit in vitro fibril- lar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 1996; 93: 452-455.
  46. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D: Aβ peptide immunization reduces behavioural impair- ment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982.
  47. Lobello K, Ryan MJ, Liu E, Rippon G, Black R: Targeting beta amyloid: a clinical review of immunotherapic approaches in Alzheimer's disease. Int J Alzheimers Dis 2012; 2012: 628070.
  48. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C: Aβ species removal after aβ42 im- munization. J Neuropathol Exp Neurol 2006; 65: 1040-1048.
  49. Galimberti D, Ghezzi L, Scarpini E: Immuno- therapy against amyloid pathology in Alz- heimer's disease. J Neurol Sci 2013; 333: 50- 54.
  50. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M: Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 2002; 298: 1379.
  51. Kerchner GA, Boxer AL: Bapineuzumab. Ex- pert Opin Biol Ther 2010; 10: 1121-1130.
  52. Samadi H, Sultzer D: Solanezumab for Alz- heimer's disease. Expert Opin Biol Ther 2011; 11: 787-798.
  53. Robert R, Lefranc MP, Ghochikyan A, Agad- janyan MG, Cribbs DH, Van Nostrand WE, Wark KL, Dolezal O: Restricted V gene usage and VH/VL pairing of mouse humoral re- sponse against the N-terminal immunodomi- nant epitope of the amyloid β peptide. Mol Immunol 2010; 48: 59-72.
  54. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Sym- monds K, Gordon MN, Morgan D: Deglyco- sylated anti-amyloid-beta antibodies elimi- nate cognitive deficits and reduce parenchy- mal amyloid with minimal vascular consequences in aged amyloid precursor pro- tein transgenic mice. J Neurosci 2006; 26: 5340-5346.
  55. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE: Amyloid-β immuni- zation effectively reduces amyloid deposition in FcRγ -/-knock-out mice. J Neurosci 2003; 23: 8532-8538.
  56. Wang YJ, Zhou HD, Zhou XF: Modified im- munotherapies against Alzheimer's disease: toward safer and effective amyloid clearance. J Alzheimers Dis 2010; 21: 1065-1075.
  57. Robert R, Wark KL: Engineered antibody ap- proaches for Alzheimer's disease immuno- therapy. Arch Biochem Biophys 2012; 526: 132-138.
  58. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, Härtig W, Grosche J, Goldsteins G, Tanila H, Koistinaho J, Koisti- naho M: Human intravenous immunoglobu- lin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 2010; 7;7: 90.
  59. Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F: Intravenous immuno- globulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-find- ing trial. Lancet Neurol 2013; 12: 233-243.
  60. Himmelstein DS, Ward SM, Lancia JK, Pat- terson KR, Binder LI: Tau as a therapeutic tar- get in neurodegenerative disease. Pharmacol Ther 2012; 136: 8-22 Review.
  61. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O: Tauopathy-like abnormalities and neuro- logic deficits in mice immunized with neuro- nal tau protein. Arch Neurol 2006; 63: 1459- 1467.
  62. Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010; 30: 16559- 16566.
  63. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M: Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pa- thology and delay of disease progression. J Biol Chem 2011; 286: 34457-34467. 71 Hyman BT: Amyloid-dependent and amy- loid-independent stages of Alzheimer disease. Arch Neurol 2011; 68: 1062-1064.

Cited by

Sorted by citations

Authors
Serpente, M., Bonsi, R., Scarpini, E., & Galimberti, D.
Affiliations
University of Milan (IT)
ORCID
Venue
Neuroimmunomodulation
Publisher
S. Karger AG
Published
2014
Volume
21
Issue
2-3
Pages
79-87
ISSN
  • 1021-7401 (ISSN-L)
  • 1423-0216
DOI
10.1159/000356529
OpenAlex
W2050604228
Cited by
87
References
6
Citations by year
2026: 4 · 2025: 7 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 13 · 2020: 1 · 2019: 10 · 2018: 5 · 2017: 9 · 2016: 9 · 2015: 7 · 2014: 7
FWCI
0.86
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • NeuroImmunoModulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, innate immunity, neuroinflammation, microglia, amyloid-beta, tau protein, disease-modifying drugs, humanized monoclonal antibody, active immunotherapy, passive immunotherapy, inflammatory mediators
MeSH terms
Alzheimer Disease, Animals, Humans, Immunity, Innate, Inflammation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review